Neurocrine Biosciences Inc (NBIX)
Fixed asset turnover
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Revenue | US$ in thousands | 2,355,100 | 1,883,200 | 1,411,600 | 1,107,700 | 994,700 |
| Property, plant and equipment | US$ in thousands | 82,600 | 70,800 | 58,600 | 58,600 | 44,600 |
| Fixed asset turnover | 28.51 | 26.60 | 24.09 | 18.90 | 22.30 |
December 31, 2024 calculation
Fixed asset turnover = Revenue ÷ Property, plant and equipment
= $2,355,100K ÷ $82,600K
= 28.51
The fixed asset turnover ratio for Neurocrine Biosciences Inc has shown a generally increasing trend over the past five years. From a value of 22.30 in December 31, 2020, the ratio increased to 28.51 by December 31, 2024. This signifies that the company has been able to generate more revenue from its fixed assets over time.
A high fixed asset turnover ratio indicates that Neurocrine Biosciences Inc is efficiently utilizing its fixed assets to generate sales. The steady increase in this ratio suggests improved operational efficiency and effective management of fixed assets over the years. It indicates that the company is making optimal use of its investments in property, plant, and equipment to drive revenue growth.
Overall, the upward trend in Neurocrine Biosciences Inc's fixed asset turnover ratio reflects positively on the company's operational performance and efficiency in utilizing its fixed assets to generate revenue. This trend may be viewed favorably by investors and stakeholders as it indicates effective resource utilization and potential for sustainable growth.
Peer comparison
Dec 31, 2024